Volume 14•Issue 6

In this update, we discuss the implementation progress of the Medicare Drug Price Negotiation Program, with particular focus on the second round of negotiations for 15 additional Part D drugs; explore the role of health technology assessment in US ...

Aim: This study aimed to estimate the economic impacts of expanded access to ketamine relative to electroconvulsive therapy (ECT) by offering intravenous ketamine to US patients with nonpsychotic treatment-resistant depression (TRD) and moderate-to-...

Aim: Direct oral anticoagulant (DOAC) switching often occurs in patients with nonvalvular atrial fibrillation (NVAF) for medical and nonmedical reasons. Limited data describe the economic consequences of DOAC switching in patients with NVAF. This study ...

Aim: We performed a feasibility assessment to systematically evaluate randomized controlled trials (RCTs) for generalized myasthenia gravis (gMG) treatments. The goal was to identify the advantages and disadvantages of different indirect treatment ...

Aim: To assess the evolution of chronic disease medication adherence factors and identify factors predictive of long-term adherence in the UAE. Materials & methods: Patients ≥18 years old; newly diagnosed with one of the following diseases: ankylosing ...

Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) is ...

For years, Canadians have faced long wait times for access to new medicines. These delays are largely attributed to complex health technology assessments, extended price negotiations and protracted provincial listing decisions. To address these ...